Brief: Tempest Therapeutics Amezalpat Data In Randomized First-Line HCC Study Shows 6-Month Improvement Versus Control Arm
20/06/2024 13:33
June 20 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST THERAPEUTICS: AMEZALPAT DATA IN RANDOMIZED
FIRST-LINE
HCC STUDY SHOWS 6-MONTH IMPROVEMENT VERSUS CONTROL ARM
* TEMPEST THERAPEUTICS INC: AMEZALPAT REMAINS WELL TOLERATED
* TEMPEST THERAPEUTICS INC: RANDOMIZED ARMS WERE GENERALLY
WELL
BALANCED AT BASELINE
Source text for Eikon: ID:nGNX5dQSVV
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T